Skip to main content
. Author manuscript; available in PMC: 2014 Oct 15.
Published in final edited form as: Clin Cancer Res. 2013 Aug 21;19(20):5798–5807. doi: 10.1158/1078-0432.CCR-13-0558

Figure 2. DFS by MYC Protein Level and Treatment Arm.

Figure 2

Figure 2

Figure 2

A. Nuclear 3+ MYC staining in ≤30% invasive tumor cells by treatment arm. B. Nuclear 3+ MYC staining in >30% invasive tumor cells by treatment arm. A: doxorubicin; C: cyclophosphamide; T: paclitaxel; H: trastuzumab. DFS Stratified by receptor and nodal status; Arm A vs B Interaction p-value = 0.71; Arm A vs C Interaction p-value = 0.40; Arm B vs C Interaction p-value = 0.17. C. Forest Plots of DFS by Nuclear MYC Protein Expression (Arm C vs A).